NeuBase Therapeutics Appoints Danith Ly, Ph.D. as Chief Scientific Officer

Dr. Ly is a leader in the field of peptide nucleic acids and the primary inventor of NeuBase’s proprietary PATrOL™ platform

PITTSBURGH, July 24, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced the appointment of Danith Ly, Ph.D., as chief scientific officer. Dr. Ly is the primary inventor of NeuBase’s peptide nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform technology, which the Company is leveraging to develop a pipeline of gene modifying therapies. Dr. Ly joins NeuBase as the Company is advancing its first PATrOL-enabled therapies through preclinical development and expanding its pipeline across rare genetic diseases as well as additional genetically-driven disorders. In addition to his role at NeuBase, Dr. Ly will maintain his faculty appointment at Carnegie Mellon University’s Mellon College of Science.

“Dr. Ly is recognized as a leader in the field of peptide nucleic acids and intelligent chemical design,” said Dietrich Stephan, Ph.D., chief executive officer of NeuBase. “His decades of innovations in this field bring unparalleled understanding of the fundamentals behind our PATrOL technology to the Company and will be invaluable as we continue to develop an expansive pipeline of PATrOL-enabled therapies for a number of indications in rare genetic disease and beyond.”

Dr. Ly added, “I am honored to be joining NeuBase at this pivotal time, as we scale the PATrOL platform from the laboratory to the clinic. I am looking forward to working closely with the entire team and am confident that we have the ability to fully realize the potential of this technology for patient populations desperately in need of transformative treatment options.”

Dr. Ly joins NeuBase in an official capacity having developed the Company’s PATrOL platform. He has over 30 years of research and development experience in nucleic acids chemistry and functional genomics, and an extensive publication report. His work has appeared in numerous high-profile journals, including Science, Nature Communications, Nature Communications Chemistry, Proceeding of the National Academy of Science and the Journal of the American Chemical Society. He is currently a professor of chemistry and a founding director of the Biomolecular Design and Discovery Institute (BDI) at Carnegie Mellon University. Prior to joining NeuBase, he co-founded PNA Innovations (now Trucode Gene Repair) and has held several industry and non-governmental organization posts, including as a scientific advisory board member at HelixBind and a member of the board of directors of Karuna Commune Enterprise. Dr. Ly holds a Ph.D. in organic chemistry from the Georgia Institute of Technology and completed postdoctoral fellowships at the University of California Berkeley and The Scripps Research Institute, in genomics and age-related genetic disease, respectively.

About NeuBase Therapeutics
NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act.  These forward-looking statements include, among other things, statements regarding the Company’s goals and plans. These forward-looking statements are distinguished by use of words such as "will," "would," "anticipate," "expect," "believe," "designed," "plan," or "intend," the negative of these terms, and similar references to future periods.  These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements.  Our forward-looking statements contained herein speak only as of the date of this press release.  Factors or events that we cannot predict, including those described in the risk factors contained in the Company’s registration statement on Form S-4, as amended, that contains a joint proxy statement/prospectus, may cause our actual results to differ from those expressed in forward-looking statements. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release, including: the Company’s plans to develop and commercialize its product candidates; the timing of initiation of the Company’s planned clinical trials; the timing of the availability of data from the Company’s clinical trials; the timing of any planned investigational new drug application or new drug application; the Company’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of the Company’s product candidates; the Company’s commercialization, marketing and manufacturing capabilities and strategy; the Company’s ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as those risks discussed under the heading "Risk Factors" in Ohr’s registration statement on Form S-4, as amended, that contains a joint proxy statement/prospectus. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

NeuBase Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
OP: (617) 535-7746

NeuBase Media Contact:
Cait Williamson, Ph.D.
LifeSci Public Relations
OP: (646) 751-4366


Source: NeuBase Therapeutics, Inc.